Literature DB >> 17108046

Incorporation of glycosylphosphatidylinositol-anchored granulocyte- macrophage colony-stimulating factor or CD40 ligand enhances immunogenicity of chimeric simian immunodeficiency virus-like particles.

Ioanna Skountzou1, Fu-Shi Quan, Sailaja Gangadhara, Ling Ye, Andrei Vzorov, Periasamy Selvaraj, Joshy Jacob, Richard W Compans, Sang-Moo Kang.   

Abstract

The rapid worldwide spread of human immunodeficiency virus (HIV) mandates the development of successful vaccination strategies. Since live attenuated HIV is not accepted as a vaccine due to safety concerns, virus-like particles (VLPs) offer an attractive safe alternative because they lack the viral genome yet they are perceived by the immune system as a virus particle. We hypothesized that adding immunostimulatory signals to VLPs would enhance their efficacy. To accomplish this we generated chimeric simian immunodeficiency virus (SIV) VLPs containing either glycosylphosphatidylinositol (GPI)-anchored granulocyte-macrophage colony-stimulating factor (GM-CSF) or CD40 ligand (CD40L) and investigated their biological activity and ability to enhance immune responses in vivo. Immunization of mice with chimeric SIV VLPs containing GM-CSF induced SIV Env-specific antibodies as well as neutralizing activity at significantly higher levels than those induced by standard SIV VLPs, SIV VLPs containing CD40L, or standard VLPs mixed with soluble GM-CSF. In addition, mice immunized with chimeric SIV VLPs containing either GM-CSF or CD40L showed significantly increased CD4(+)- and CD8(+)-T-cell responses to SIV Env, compared to standard SIV VLPs. Taken together, these results demonstrate that the incorporation of immunostimulatory molecules enhances humoral and cellular immune responses. We propose that anchoring immunostimulatory molecules into SIV VLPs can be a promising approach to augmenting the efficacy of VLP antigens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17108046      PMCID: PMC1797543          DOI: 10.1128/JVI.01692-06

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

Review 1.  Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation.

Authors:  J Reimann; R Schirmbeck
Journal:  Immunol Rev       Date:  1999-12       Impact factor: 12.988

2.  Plasma membrane rafts play a critical role in HIV-1 assembly and release.

Authors:  A Ono; E O Freed
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

3.  CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse.

Authors:  R A Tripp; L Jones; L J Anderson; M P Brown
Journal:  J Immunol       Date:  2000-06-01       Impact factor: 5.422

4.  Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets.

Authors:  H Hochrein; K Shortman; D Vremec; B Scott; P Hertzog; M O'Keeffe
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

5.  Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12.

Authors:  A Krug; A Towarowski; S Britsch; S Rothenfusser; V Hornung; R Bals; T Giese; H Engelmann; S Endres; A M Krieg; G Hartmann
Journal:  Eur J Immunol       Date:  2001-10       Impact factor: 5.532

6.  A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice.

Authors:  R Xiang; F J Primus; J M Ruehlmann; A G Niethammer; S Silletti; H N Lode; C S Dolman; S D Gillies; R A Reisfeld
Journal:  J Immunol       Date:  2001-10-15       Impact factor: 5.422

7.  CD40 expression and function on human dermal microvascular endothelial cells: role in cutaneous inflammation.

Authors:  S R Singh; K Casper; S Summers; R A Swerlick
Journal:  Clin Exp Dermatol       Date:  2001-07       Impact factor: 3.470

8.  Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine.

Authors:  C D Harro; Y Y Pang; R B Roden; A Hildesheim; Z Wang; M J Reynolds; T C Mast; R Robinson; B R Murphy; R A Karron; J Dillner; J T Schiller; D R Lowy
Journal:  J Natl Cancer Inst       Date:  2001-02-21       Impact factor: 13.506

9.  Plasmid vaccine expressing granulocyte-macrophage colony-stimulating factor attracts infiltrates including immature dendritic cells into injected muscles.

Authors:  D Haddad; J Ramprakash; M Sedegah; Y Charoenvit; R Baumgartner; S Kumar; S L Hoffman; W R Weiss
Journal:  J Immunol       Date:  2000-10-01       Impact factor: 5.422

Review 10.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-cell responses: what we do and don't know.

Authors:  Yufang Shi; Catherine H Liu; Arthur I Roberts; Jyoti Das; Guangwu Xu; Guangwen Ren; Yingyu Zhang; Liying Zhang; Zeng Rong Yuan; Hung Sheng William Tan; Gobardhan Das; Satish Devadas
Journal:  Cell Res       Date:  2006-02       Impact factor: 25.617

View more
  33 in total

1.  Incorporation of CD40 ligand into SHIV virus-like particles (VLP) enhances SHIV-VLP-induced dendritic cell activation and boosts immune responses against HIV.

Authors:  Rongxin Zhang; Sheng Zhang; Min Li; Changyi Chen; Qizhi Yao
Journal:  Vaccine       Date:  2010-05-14       Impact factor: 3.641

2.  Human immunodeficiency virus-like particles activate multiple types of immune cells.

Authors:  Gangadhara Sailaja; Ioanna Skountzou; Fu-Shi Quan; Richard W Compans; Sang-Moo Kang
Journal:  Virology       Date:  2007-02-05       Impact factor: 3.616

3.  EBV LMP1, a viral mimic of CD40, activates dendritic cells and functions as a molecular adjuvant when incorporated into an HIV vaccine.

Authors:  Sachin Gupta; James M Termini; Liguo Niu; Saravana K Kanagavelu; Helena Schmidtmayerova; Victoria Snarsky; Richard S Kornbluth; Geoffrey W Stone
Journal:  J Leukoc Biol       Date:  2011-05-17       Impact factor: 4.962

4.  Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.

Authors:  Elena V Vassilieva; Haripriya Kalluri; Devin McAllister; Misha T Taherbhai; E Stein Esser; Winston P Pewin; Joanna A Pulit-Penaloza; Mark R Prausnitz; Richard W Compans; Ioanna Skountzou
Journal:  Drug Deliv Transl Res       Date:  2015-08       Impact factor: 4.617

5.  Co-delivery of GPI-anchored CCL28 and influenza HA in chimeric virus-like particles induces cross-protective immunity against H3N2 viruses.

Authors:  Teena Mohan; Jongrok Kim; Zachary Berman; Shelly Wang; Richard W Compans; Bao-Zhong Wang
Journal:  J Control Release       Date:  2016-05-10       Impact factor: 9.776

6.  Protection against lethal challenge by Ebola virus-like particles produced in insect cells.

Authors:  Yuliang Sun; Ricardo Carrion; Ling Ye; Zhiyuan Wen; Young-Tae Ro; Kathleen Brasky; Anysha E Ticer; E Ellen Schwegler; Jean L Patterson; Richard W Compans; Chinglai Yang
Journal:  Virology       Date:  2008-11-04       Impact factor: 3.616

7.  Incorporation of membrane-anchored flagellin into influenza virus-like particles enhances the breadth of immune responses.

Authors:  Bao-Zhong Wang; Fu-Shi Quan; Sang-Moo Kang; Jadranka Bozja; Ioanna Skountzou; Richard W Compans
Journal:  J Virol       Date:  2008-09-10       Impact factor: 5.103

Review 8.  Virus-like particles as universal influenza vaccines.

Authors:  Sang-Moo Kang; Min-Chul Kim; Richard W Compans
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

Review 9.  Influenza vaccines based on virus-like particles.

Authors:  Sang-Moo Kang; Jae-Min Song; Fu-Shi Quan; Richard W Compans
Journal:  Virus Res       Date:  2009-04-15       Impact factor: 3.303

10.  Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine.

Authors:  Ioanna Skountzou; Maria del Pilar Martin; Baozhong Wang; Ling Ye; Dimitrios Koutsonanos; Will Weldon; Joshy Jacob; Richard W Compans
Journal:  Vaccine       Date:  2009-08-03       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.